Insomnia News and Research

Latest Insomnia News and Research

Study demonstrates efficacy of CONCERTA in treating ADHD in presence of comorbid learning disability

Study demonstrates efficacy of CONCERTA in treating ADHD in presence of comorbid learning disability

Shire announces study results of Vyvanse Capsules CII for treatment of ADHD in adolescents

Shire announces study results of Vyvanse Capsules CII for treatment of ADHD in adolescents

Mylan Pharmaceuticals introduces Temazepam Capsules USP, 7.5 mg

Mylan Pharmaceuticals introduces Temazepam Capsules USP, 7.5 mg

FDA grants priority review for Alkermes' VIVITROL sNDA for opioid dependence

FDA grants priority review for Alkermes' VIVITROL sNDA for opioid dependence

Filing of Clinical Data's NDA for vilazodone accepted for FDA review

Filing of Clinical Data's NDA for vilazodone accepted for FDA review

New findings on INTUNIV Extended Release Tablets presented at major psychiatric meeting

New findings on INTUNIV Extended Release Tablets presented at major psychiatric meeting

Psychiatrists should be included in disaster first-response teams

Psychiatrists should be included in disaster first-response teams

Flibanserin benefits pre-menopausal women with Hypoactive Sexual Desire Disorder

Flibanserin benefits pre-menopausal women with Hypoactive Sexual Desire Disorder

Transcept Pharmaceuticals reports revenue of $3.13M for first-quarter 2010

Transcept Pharmaceuticals reports revenue of $3.13M for first-quarter 2010

Merck hosts R&D and Business Briefing

Merck hosts R&D and Business Briefing

Alexza Pharmaceuticals first-quarter net loss increases to $13.4 million

Alexza Pharmaceuticals first-quarter net loss increases to $13.4 million

Takeda enters co-promotion agreement with Janssen Pharma for VELCADE

Takeda enters co-promotion agreement with Janssen Pharma for VELCADE

Data comparing NUCYNTA to oxycodone IR for osteoarthritis pain presented at 29th APS

Data comparing NUCYNTA to oxycodone IR for osteoarthritis pain presented at 29th APS

Meda acquires exclusive rights for use of flupirtine to treat fibromyalgia from Adeona Pharmaceuticals

Meda acquires exclusive rights for use of flupirtine to treat fibromyalgia from Adeona Pharmaceuticals

Labopharm's first-quarter fiscal 2010 revenues from product sales decrease $0.4M to $3.2M

Labopharm's first-quarter fiscal 2010 revenues from product sales decrease $0.4M to $3.2M

Alexza Pharmaceuticals secures $15M working capital loan from Hercules Technology Growth Capital

Alexza Pharmaceuticals secures $15M working capital loan from Hercules Technology Growth Capital

Alexza Pharmaceuticals announces filing of universal shelf registration statement with SEC

Alexza Pharmaceuticals announces filing of universal shelf registration statement with SEC

Data from Phase IV study of Bystolic tablets in Hispanic patients with hypertension presented at ASH 2010

Data from Phase IV study of Bystolic tablets in Hispanic patients with hypertension presented at ASH 2010

TGRD presents positive results from Phase 3 studies of azilsartan medoxomil for lowering SBP at 25th ASH

TGRD presents positive results from Phase 3 studies of azilsartan medoxomil for lowering SBP at 25th ASH

New classification of depressive subtypes of depression proposed

New classification of depressive subtypes of depression proposed

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.